COSMIX is a development stage biotechnology company that is using proprietary technologies to develop a range of biotherapeutic agents as well as highly specific binding peptides for use in the diagnostic, imaging and biopurifications industries. The Company uses innovative mRNA Display Technology to generate highly selective affinity ligands as reagents for its partners in the life science industry. Its bioprocessing products enable an improved efficiency of current bioprocessing procedures. In addition, the Company is developing novel biotherapeutics that offer the ability to be more cost effective, safer and less toxic. COSMIX intends to utilize its proprietary approaches to build its own proprietary drug pipeline.